Key words: cholelithiasis, cholecystectomy, postcholecystectomical syndrome, ursodeoxycholic acid, mebeverin, lithogenicity of the bile Pathology of the biliary tract is an acute problem of the modern medicine. In recent decades, both in Russia and abroad, despite some advances therapy associated with the appearance on the market of new pharmacological tools for effective correction of functional disorders of the digestive system, there is a clear upward trend in the incidence of biliary system. And this trend is characterized by stability.
cholecystitis and cholelithiasis, which occurs as a result of violations of the colloidal stability of bile and joining the inflammatory process. Interest in the problem is also due to frequent involvement in the pathological process of adjacent organs (liver, pancreas, stomach and duodenum) and the occurrence of severe complications leading to disability.
The most common form of gallbladder disease is cholelithiasis (gallstones).
According to the results of statistical studies in recent years, cholelithiasis suffer almost every five women and one man 10 . Approximately one quarter of the population over age 60 and 1/3 of the population older than 70 years have gallstones.
There are many factors that contribute to stone formation. Mnemonic for remembering risk factors of cholesterol gallstones are 5F: Fat -fat (overweight), Forty -forty (age about 40 years or more), Female -woman, Fertilechildbearing age (estrogen, increased premenopausal leads to an increase cholesterol levels in bile and decrease motor-evacuation function of the gallbladder) and Fairblond or blonde. Other risk factors include a high intake of fat and carbohydrates, a sedentary lifestyle, type 2 diabetes and dyslipidemia (increased triglycerides and low HDL). A diet high in fats and carbohydrates in the formation of obesity predisposes that leads to increased synthesis of cholesterol and bile hypersaturation. However, no direct correlation between excess fat intake and the risk of gallstone disease is not established, as studies on this subject have yielded conflicting results. Number of suspected "trigger mechanisms" are also numerous: an imbalance in the system enzyme HMG-CoA reductase and 7α-hydroxylase regulating the synthesis of cholesterol and its conversion into bile acids, reduction of cytochrome P-450 involved in the hydroxylation, the change in the content of lysolecithin , cholesterol, mucin, taurocholate, etc. Has not lost its relevance today and lithogenesis classical theory based on the complex: lipid metabolism, inflammation and cholestasis.
Gallstone disease in most cases are asymptomatic. Gallbladder disease can clinically manifested symptoms: pain in the right hypochondrium or epigastrium radiating to the right shoulder and forcing the patient to lie down, and not relieved by defecation.
Most often the pain is constant and not cramping in nature. A Danish study indicates the prevalence of gallstones that "night pain in the right upper quadrant" is the clearest symptom in men, and the "strong and oppressive pain, provoked by fatty food" is a symptom that best correlates with the presence of gallstones in women. Typically, the second and the third part biliary subtypes, as well as in some cases the type of pancreatic DSO treated conservatively. Noteworthy Milwaukee classification for DSO, since it is defined and stages of research and methods of treatment, it is very convenient in practice, surgeons and gastroenterologists in practice (Table 1) .  mebeverin metabolizes in the small intestine and enters the liver, and then the systemic circulation as already inactive metabolite without exerting any systemic effect.
Effect after administration of mebeverin occurs rapidly (within 20-30 minutes) and proceeds at around 12 hours, which makes possible its acceptance twice daily (prolonged form), while for older patients require dose adjustments. Mebeverin hydrochloride drug in these patients can be used for a long time, which is especially important for patients with DSO after CE.
Thus, the timely and proper evaluation of clinical symptoms developing in patients after CE, gives you the opportunity to choose the appropriate treatment and as a result improve the quality of life of patients with diseases of the hepatobiliary system.
